Table 7.
COVID-19 outcomes in 25OHD-suficient, calcifediol-supplemented patients compared to unsupplemented, 25OHD-suficient patients
| Calcifediol treated and serum 25OHD ≥ 30 ng/ml (n = 16,276) | Untreated controls with serum 25OHD < 20 ng/ml (n = 7616) | Univariate analysis3 | Multivariate analysis4 | |||
|---|---|---|---|---|---|---|
| HR (CI 95%) | p | HR (CI 95%) | p | |||
| SARS-CoV2 infection1, n (%) | 535 (3.3%) | 430 (5.6%) | 0.58 (0.51–0.66) | < 0.001 | 0.69 (0.61–0.79) | < 0.001 |
| Severe COVID-192, n (%) | 100 (0.6%) | 99 (1.3%) | 0.47 (0.36–0.62) | < 0.001 | 0.61 (0.46–0.81) | 0.001 |
| COVID-19 mortality, n (%) | 88 (0.5%) | 96 (1.3%) | 0.43 (0.32–0.57) | < 0.001 | 0.56 (0.42–0.76) | < 0.001 |
25OHD 25-hydroxyvitamin D
1Positive PCR or clinical diagnosis of SARS-CoV2 infection
2Composite outcome of need for non-invasive mechanical ventilation, orotracheal intubation, mechanical ventilation, intensive care unit admission or death
3Unadjusted Cox regression analysis
4Cox regression analysis controlling for all covariates